ClinicalTrials.gg
CompletedNCT02269176Updated Oct 21, 2014

Efficacy and Safety of Telmisartan and Losartan in Primary Hypertension

A Phase 3 interventional study of Low dose of telmisartan and High dose of telmisartan in Hypertension, sponsored by Boehringer Ingelheim. Completed. Per ClinicalTrials.gov, last updated 2014-10-21.

Sponsored by Boehringer Ingelheim · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
330
Allocation
Randomized
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 122 studies in Hypertension by Boehringer Ingelheim — 1 open to participants now, 1 under way, 1 of them phase 3. Hypertension · Boehringer Ingelheim.

Enrollment
42nd of 74
330 · median 381
Started
2000
with 10 others
Phase 3
43 of 122
1 open now
Registered
119th of 122
by date

Among the 122 studies in Hypertension by Boehringer Ingelheim, this one is the 42nd largest by enrollment of the 74 interventional ones that give a count, is one of 11 that started in 2000, is one of 43 in phase 3, and was the 119th registered.

Hypertension

6,122 studies on the registry are indexed under Hypertension; 913 are open to participants now.

Browse Hypertension studies →

Open to participants now

1 of the 122 studies in Hypertension by Boehringer Ingelheim is open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

Who these studies take

Of the 563 Hypertension studies recruiting now, 266 (47%) set no upper age limit and 200 (36%) stop at 75 or younger; 40 take children under 18; 139 take healthy volunteers.

This study: all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 122 studies in Hypertension by Boehringer Ingelheim, or all of them as a file.
02

Study summary

Using Losartan as a comparator, to evaluate the efficacy and safety of telmisartan in the treatment of the mild to moderate primary hypertension patients in China

03

Conditions studied

  • Hypertension

Browse trials for

04

Who can participate

Ages eligible
Child (0–17), Adult (18–64), Older adult (65+)
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Mild to moderate primary hypertension, the mean sitting valley value of diastolic blood pressure (DBP) ≥ 95 and \< 110 mmHg, and the mean sitting valley value of systolic blood pressure (SBP) \< 180 mmHg

Exclusion criteria

Exclusion Criteria:

  • Not specified
05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double
Enrollment
330 participants (actual)

Study arms

  • Experimental
    Telmisartan

    Low dose of telmisartan, uptitrated to high dose in case no sufficient effect is observered

    Drug: Low dose of telmisartan · Drug: High dose of telmisartan

  • Active comparator
    Losartan

    Low dose of losartan, uptitrated to high dose in case no sufficient effect is observered

    Drug: Low dose of losartan · Drug: High dose of losartan

Interventions

  • DrugLow dose of telmisartan
  • DrugHigh dose of telmisartan
  • DrugLow dose of losartan
  • DrugHigh dose of losartan
06

What researchers measure

Primary outcomes

  1. Changes in mean sitting valley value of DBP

    The valley value of blood pressure refers to the blood pressure measured prior to the next administration of antihypertensives

    Time frame: 8 weeks after start of treatment

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2000 and a primary completion of Jan 2001. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 20, 2014
First posted
Oct 21, 2014
Start
Jul 2000
Primary completionActual
Jan 2001
Last update
Oct 21, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 21, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02269176
Responsible party
Sponsor
First posted
Oct 21, 2014
Start date
Jul 2000
Primary completion
Jan 2001
Last update
Oct 21, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion